Patents by Inventor Andrew H.-J. Wang
Andrew H.-J. Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230233699Abstract: The present invention relates to oligonucleotide conjugates and preparation and applications thereof. In particular, the present invention relates to an oligonucleotide conjugated to a biomolecule (e.g. an antibody) and/or an agent of interest (e.g. a drug). In certain embodiments, the oligonucleotide of the present invention is a hybridized complex of a single strand oligonucleotide carrying a biomolecule and a complementary strand oligonucleotide bearing an agent of interest where the hybridized nucleotide segment acts as a linker to link the biomolecule and the agent of interest in one molecule.Type: ApplicationFiled: April 15, 2021Publication date: July 27, 2023Applicant: ACADEMIA SINICAInventors: Andrew H.-J. WANG, Cheng-Chung LEE, Nai-Shu HSU, Wen-Chih KUO
-
Publication number: 20230220065Abstract: Disclosed herein are anti-IL-1? antibodies capable of binding to human IL-1? and blocking its biological activities. Also provided herein are pharmaceutical compositions comprising the anti-IL-1? antibodies and therapeutic and diagnostic uses of such antibodies.Type: ApplicationFiled: June 15, 2021Publication date: July 13, 2023Applicant: ACADEMIA SINICAInventors: Andrew H.-J. WANG, Wen-Chih KUO, Cheng-Chung LEE, An-Suei YANG
-
Patent number: 9856483Abstract: Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (QC) with E45Q mutation, so as to autonomously produce a target protein having a N-terminal pyroglutamate (pGlu) residue in a host cell. The first fusion protein is composed of a maltose binding protein (MBP) and a tobacco etch virus protease (TEVP); and the second fusion protein includes in sequence, a thioredoxin, a S-tag, a linker having a TEVP recognition site therein, a target protein, and a (His)-6-tag. The second fusion protein is cleaved by the TEVP that is expressed by the first fusion protein, and then catalyzed by QC with E45Q mutation so as to autonomously produce the target protein having a N-terminal pGlu residue in the host cell.Type: GrantFiled: March 18, 2015Date of Patent: January 2, 2018Inventors: Andrew H. -J. Wang, Kai-Fa Huang, Yan-Ping Shih
-
Publication number: 20160273015Abstract: Disclosed herein is an expression system and uses thereof. The expression system comprises two vectors that express two fusion proteins and a glutaminyl cyclase (QC) with E45Q mutation, so as to autonomously produce a target protein having a N-terminal pyroglutamate (pGlu) residue in a host cell. The first fusion protein is composed of a maltose binding protein (MBP) and a tobacco etch virus protease (TEVP); and the second fusion protein includes in sequence, a thioredoxin, a S-tag, a linker having a TEVP recognition site therein, a target protein, and a (His)-6-tag. The second fusion protein is cleaved by the TEVP that is expressed by the first fusion protein, and then catalyzed by QC with E45Q mutation so as to autonomously produce the target protein having a N-terminal pGlu residue in the host cell.Type: ApplicationFiled: March 18, 2015Publication date: September 22, 2016Inventors: Andrew H. -J. Wang, Kai-Fa Huang, Yan-Ping Shih
-
Patent number: 9067985Abstract: An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a T7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to Asn94 of SEQ ID NO: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant Haloarcula marismortui bacteriorhodopsin/D94N (HmBRI/D94N) or a Haloquadratum walsbyi bacteriorhodopsin (HwBR); b) a target membrane protein; and c) a T7 promoter, operably linked to the mutant HmBRI/D94N or HwBR and the target membrane protein. Host cells comprising the expression vector or the fusion membrane protein expression system and methods of using the same are also disclosed.Type: GrantFiled: September 30, 2013Date of Patent: June 30, 2015Assignee: ACADEMIA SINICAInventors: Andrew H.-J. Wang, Min-Feng Hsu, Chii-Shen Yang, Hsu-Yuang Fu
-
Publication number: 20140099667Abstract: An expression vector is disclosed, which comprises: a) a polynucleotide sequence encoding a bacteriorhodopsin or a mutant bacteriorhodopsin; b) a multiple cloning site; c) a T7 promoter, d) a polyhistidine tag; e) a first protease cleavage site; f) optionally a second protease cleavage site; and g) optionally a linker; wherein the mutant bacteriorhodopsin comprises the residue corresponding to Asn94 of SEQ ID NO: 1. Also disclosed is a fusion membrane protein expression system, which comprises: a) a polynucleotide sequence encoding a mutant Haloarcula marismortui bacteriorhodopsin/D94N (HmBRI/D94N) or a Haloquadratum walsbyi bacteriorhodopsin (HwBR); b) a target membrane protein; and c) a T7 promoter, operably linked to the mutant HmBRI/D94N or HwBR and the target membrane protein. Host cells comprising the expression vector or the fusion membrane protein expression system and methods of using the same are also disclosed.Type: ApplicationFiled: September 30, 2013Publication date: April 10, 2014Applicant: Academia SinicaInventors: Andrew H.-J. WANG, Min-Feng` Hsu, Chii-Shen Yang, Hsu-Yuang Fu
-
Publication number: 20130101571Abstract: Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants.Type: ApplicationFiled: March 23, 2012Publication date: April 25, 2013Applicant: Academia SinicaInventors: Andrew H-J. Wang, Shiuan-Woei Lin Wu, Fu-Chuo Peng, Che-An Wu
-
Publication number: 20120244138Abstract: Methods and compositions for detoxifying nitrobenzodiazepines with nitroreductase mutants.Type: ApplicationFiled: March 23, 2012Publication date: September 27, 2012Applicant: Academia SinicaInventors: Andrew H-J. Wang, Shiuan-Woei Lin Wu, Fu-Chuo Peng, Che-An Wu
-
Patent number: 7892771Abstract: A crystalline structure of glutaminyl cyclase (QC) is described. Also described are the methods of preparing the crystalline structure of QC and the methods for identifying candidate inhibitors of QC. In addition, a structural basis for the rational design or identification of new inhibitors that may be used to treat QC-associated disorders is also described.Type: GrantFiled: April 24, 2009Date of Patent: February 22, 2011Assignee: Academia SinicaInventors: Andrew H.-J. Wang, Kai-Fa Huang
-
Patent number: 7846719Abstract: A vector for expressing a soluble glutaminyl cyclase (QC) in bacterial cells is described. The vector contains a sequence encoding a fusion QC, which has a fusion protein tag selected from a Nus protein tag or a thioredoxin (Trx) tag, a QC, and a linker having at least one (His)x-tag between the QC and the fusion protein tag, in which x is an integer of at least 6. Methods for expressing a soluble glutaminyl cyclase (QC) by the vector are also described.Type: GrantFiled: January 13, 2006Date of Patent: December 7, 2010Assignee: Academia SinicaInventors: Andrew H.-J. Wang, Kai-Fa Huang
-
Publication number: 20100035300Abstract: A cis-TEVP fusion protein including a TEVP protease, a TEVP cleavage site and a target protein provide a platform for expression of the target protein. A trans-TEVP fusion protein including a TEVP cleavage site and a target protein, the amino-terminal portion of the target protein adjacent to the C-terminal portion of the TEVP cleavage site, the amino acidic residue in position P2 of the TEVP cleavage site being a Valine also produces the target protein by the same process. A cis-TEVP fusion protein system comprising the first fusion protein and a suitable host cell; a trans-TEVP fusion protein system comprising the second fusion protein and a suitable host cell; associated methods to produce target proteins, and kits of parts are also disclosed herein.Type: ApplicationFiled: February 27, 2006Publication date: February 11, 2010Inventors: Andrew H.-J. Wang, Ting-Fang Wang, Yan-Ping Shih, Hui-Chung Wu, Su-Ming Hu
-
Publication number: 20090203045Abstract: A crystalline structure of glutaminyl cyclase (QC) is described. Also described are the methods of preparing the crystalline structure of QC and the methods for identifying candidate inhibitors of QC. In addition, a structural basis for the rational design or identification of new inhibitors that may be used to treat QC-associated disorders is also described.Type: ApplicationFiled: April 24, 2009Publication date: August 13, 2009Applicant: ACADEMIA SINICAInventors: Andrew H.-J. WANG, Kai-Fa HUANG
-
Patent number: 7572614Abstract: A crystalline structure of glutaminyl cyclase (QC). is described. Also described are the methods of preparing the crystalline structure of QC and the methods for identifying candidate inhibitors of QC. In addition, a structural basis for the rational design or identification of new inhibitors that may be used to treat QC-associated disorders is also described.Type: GrantFiled: February 24, 2006Date of Patent: August 11, 2009Assignee: Academia SinicaInventors: Andrew H.-J. Wang, Kai-Fa Huang